High expression of cancer stem cell (CSC) marker CD133 has been used as a predictor for prognosis in colorectal cancer (CRC), suggesting that enumeration of CSCs, using CD133, is predictive for disease progression. However, we showed recently that both CD133 mRNA and protein are not downregulated during differentiation of colon CSCs, pointing to an alternative reason for the prognostic value of CD133. We therefore set out to delineate the relation between CD133 expression and prognosis.
INTRODUCTION
In order to develop a better strategy for defining which colorectal cancer (CRC) patients should receive adjuvant chemotherapy after surgery, reliable markers for predicting relapse have been studied extensively (reviewed in [1] ). Mutations in signaling pathways are used, but also expression levels of proteins that are suggested to identify the cancer stem cell (CSC) fraction of the tumor [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . CSCs, the driving force behind tumor initiation, growth and metastasis, are hypothesized to be crucial for patient prognosis. This current model hypothesizes that the expression of CSC markers correlates to the number of CSCs within a tumor and thereby to the patient prognosis. The following markers are used to identify CRC CSCs: CD24 [16] , CD29 [16] , CD44 [17] [18] [19] , CD133 [16, [20] [21] [22] , CD166 [18] , Lgr5 [23] and ALDH1A1 [24] . Previously, CD133 is indeed identified as an independent prognostic marker for CRC by showing that either high expression of CD133 mRNA or intense CD133 staining in immunohistochemistry (IHC) relates to poor relapse-free/overall survival [2-7, 13, 15] (Suppl. Table 1 ). As CD133 marks CSCs, it was postulated that high CD133 expression correlates to more CSCs and thus more tumorigenic and/or metastatic capacity. However, CD133 is not only expressed on CSCs, but also on differentiated cells, both at the mRNA [25] and protein level [25, 26] . Previously, we found that the use of CD133 as a CSC marker depends on the availability of the AC133 epitope and is not determined by CD133 mRNA or protein expression, which remain unchanged during in vitro and in vivo differentiation of colon CSCs [27] . Recently, it was confirmed that N-glycosylation of CD133 affects the cell surface recognition of AC133 [28] . Altogether, this suggests that the prognostic value of CD133 in CRC is not due to an enumeration of CSCs.
Other factors are shown to correlate to poor prognosis in CRC, like mutations in tumor suppressor gene p53 [29, 30] or proto-oncogenes like K-Ras [31, 32] and B-Raf [33] . The prognostic value of K-Ras although was not identified in large stage II-III cohort of CRC [34] . p53 is frequently mutated or lost (60-70%) in CRC, while K-Ras is mutated in approximately 40% of all CRCs [35] . B-Raf is directly downstream of Ras and is mutated at position V600 in 5-10% of all CRC cases. The latter two mutations both lead to aberrant activation of the Ras-Raf-MEK-ERK pathway [35, 36] and are mutually exclusive in tumors [37] .
To understand the role of CD133 expression levels in CRC prognosis, we analyzed a stage II CRC patient set for specific mutations and expression of CSC markers by microarray and qPCR. We found that high CD133 expression, in contrast to other CSC markers, can predict relapse-free survival. However, high CD133 expression was related to mutations in KRas or B-Raf. We confirmed that CD133 is indeed regulated by the RAS-RAF-MEK-ERK K-means clustering was performed by in-house-developed software. Clusters were identified by GSEA (http://www.broadinstitute.org/gsea/index.jsp).
Cell culture and MEK inhibition
HCT116, HKH2, Dld1 and DKO4 were kindly provided by Onno Kranenburg (Department of Surgery, University Medical Center Utrecht, the Netherlands), and cultured as previously described [44] . CSC lines, approved by the medical ethical committee of the Academic Medical Center and the University of Palermo, were derived and cultured as described previously [22] . MEK inhibition was performed with 10 μM U0126 (#9903, Bioke) for 24h.
Methylation was inhibited by 2 μM 5-aza-deoxycytidine for 24h. After treatment with U0126, cells were analyzed for ERK phosphorylation either by western blot. The antibodies used for Western blot were p44/42MAPK (ERK1/2) and phospho-p44/42MAPK (ERK1/2) (Thr202/Tyr204) (BIOKE, Leiden, NL).
FACS analysis
Cells were stained with CD133-PE (AC133, Miltenyi) or mIgG1-PE (Miltenyi) as isotype control for 20min at 4°C in PBA (PBS containing 1% bovine serum albumin and 0.02% sodium azide). For intracellular detection of pERK of LM5, phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (Alexa-Fluor488 Conjugate) or rabbit IgG isotype control (AlexaFluor488 Conjugate) (BIOKE, Leiden, NL) was used. Briefly, cells were washed with cold PBS and fixed with 4% paraformaldehyde at 37ºC for 10min. After fixation, cells were permeabilized in 90% ice-cold methanol for 30min. Next, cells were stained for 1hr in PBA at a dilution of 1:50, washed and subsequently analyzed. FACS analysis was performed on the FACSCanto and analysis was performed with Flowjo software.
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RESULTS

CD133 is a predictor for poor prognosis in relapse-free survival
Previously, several groups showed that CD133 expression, analyzed by mRNA expression or IHC, can be used to predict prognosis in CRC [2-7, 13, 15] (Suppl. Table 1) . We used our AMC-AJCCII-90 CRC patient set to study CD133 as a prognostic marker. Isolation of RNA from these tumor samples and subsequent microarray analysis was performed to determine the expression level of CD133. The median expression level of CD133 was used to separate the cohort in two groups. In five cases, CD133 expression levels were not above background values and these tumors were excluded from further analyses. Using this approach, we observed that tumors in the CD133 high group expressed on average 3.7-fold more CD133 compared to the CD133 low group. Validation of the microarray CD133 expression data with qPCR showed a very significant correlation between the microarray and the qPCR data (Fig.1B ). In agreement with previous studies, high CD133 expression predicted poor relapsefree survival with a significance of p=0.0182 (Fig.1A) . Chi-square analysis of clinicopathological features showed that elevated CD133 expression was associated with metastasis and local recurrence (p=0.026 and p=0.017, respectively), but not with gender, differentiation grade, location of the tumor or age of the patient at surgery (Suppl. Table 3 ).
Other CSC markers do not predict prognosis CD133 expression levels have been suggested to predict prognosis, because they identify the CSC fraction of the tumor [2-7, 13, 15] . We therefore hypothesized that expression of other CSC markers should also be able to predict patient outcome. Several colon CSC markers, like CD24, CD29, CD44, CD166, Lgr5 and ALDH1A1, were analyzed for their prognostic value.
As reported before [24] , of these only ALDH1A1 showed an association with prognosis when using the median value of expression was used, while all other CSC markers failed to show any prognostic value ( Fig.2A) . Only when the highest quartile was used to divide the groups, also CD44 showed some prognostic value (Suppl. Fig.1 ). Strikingly, some of the CSC markers, like CD24 and Lgr5, even displayed an opposite trend, with high expression of the marker relating to good prognosis. This is a counter-intuitive finding as these CSC markers should all be highly expressed in the same cell population (the CSCs). However, closer evaluation of the relation between CD133 expression and the other CSC markers showed no significant difference in CSC marker expression was found between the CD133 high and CD133 low group (Fig.2B) . Furthermore, the expression of CSC markers did not correlate to each other (Suppl. Fig.2 ). This suggests that even though isolated CSC markers may predict
Research. expression as determined by the microarray. In agreement with our earlier observations [27] , these sections reveal that CD133 expression is detected in a large part of the tumor cells when using paraformaldehyde-fixed frozen sections and that the level of expression correlates with the mRNA expression data (Fig.2C) . We therefore conclude that CD133 levels do not correlate to CSC numbers and that an alternative explanation must exist as to why the CSC marker CD133 is related to poor prognosis in CRC.
High expression of CD133 associates with K-Ras and B-Raf mutations
We hypothesized that a mutation could be responsible for the prognostic potential of CD133.
Therefore, all tumors were analyzed for microsatellite instability (MSI) status and mutations in p53, K-Ras and B-Raf. Around 28% of the tumors were MSI, 29% carried a p53 mutation, whereas K-Ras and B-Raf mutations were found in respectively 24% and 20% of the tumor set. There was no significant difference in MSI and mutations in p53 and K-Ras between the Table 1 ). Then, we analyzed if CD133 was an independent prognostic marker by comparing univariate and multivariate Cox regression analyses and found that CD133 was independent of any of the clinicopathological features, but was dependent on K-Ras and B-Raf mutations (Table 2) . Patients with a K-Ras or B-Raf mutated CRC have been shown to have a worse prognosis [31] [32] [33] , although this has recently been contested for K-Ras mutations [45] . A link between CD133 expression and activation of the Ras-Raf-MEK-ERK pathway, specifically by B-RAF mutations could therefore explain the prognostic value of CD133.
Disruption of mutant K-Ras or downstream signaling decreases CD133 expression
Previously, it has been shown that activation of the Ras-Raf-MEK-ERK pathway results in activation of promoter 5 of the CD133 gene, thereby inducing CD133 expression [46] . Therefore, mutations in K-Ras/B-Raf could result in increased CD133 expression. To investigate this, two CRC cell lines HCT116 and Dld1 were used, which both harbor an activating mutation in one allele of the K-Ras gene. By gene-targeting of the mutant K-Ras allele, derivative lines that only contain wild-type K-Ras were produced [44] . These wild-type K-Ras HCT116 and Dld1 lines display reduced growth in vitro and in vivo [44] . We used the parental lines (HCT116 and Dld1) and their targeted offspring (called HKH2 and DKO4 respectively) to study the CD133 expression in the presence or absence of mutant K-Ras.
HCT116 cells had high expression of CD133 shown by FACS and qPCR. In contrast, expression of CD133 was significantly lower in the wild-type K-Ras derivative HKH2 (Fig.3A) . In contrast to HCT116, Dld1 and DKO4 do not express CD133, which is due to specific promoter methylation [47] (Suppl. Fig.3A-B) . To determine whether K-Ras mutation also enhances CD133 expression in this cell line, we first treated Dld1 and DKO4 cells with 5-aza-deoxycytidine, an inhibitor of DNA methylation, to alleviate this repression. Treatment of Dld1 with 5-aza-deoxycytidine resulted in a small shift in the FACS profiles pointing to a low expression of CD133. However, in the wild-type K-Ras derivative DKO4 this CD133 was lost again, which was also reflected on the mRNA level (Fig.3A) . So, disruption of mutant K-Ras is decreasing the expression of CD133 both on the level of mRNA and protein.
Since these isogenic lines were kept in culture for a large number of passages they may have acquired more difference than only their Ras status. We therefore decided to directly test the effect of Ras pathway inhibition by treatment of CRC lines with a potent MEK inhibitor U0126. Inhibition of MEK resulted in a strong reduction of ERK phosphorylation (Suppl. Fig.3C-D) . Moreover, MEK inhibition reduced the CD133 mRNA and protein expression in HCT116 and LS411N (Fig.3B-C) . In addition, treatment of two established colon spheroid cultures derived from a primary CRC [16] , having high CD133 expression, with U0126 resulted in reduced CD133 mRNA and protein expression (Fig.3D , Supp. Fig.3E ). These data show that CD133 expression is dependent on the activity of the Ras-Raf-MEK-ERK pathway.
Activated K-Ras gene expression signature correlates to CD133 expression
Although K-Ras and B-Raf mutations both lead to activation of the Ras-Raf-MEK-ERK pathway, alternative means may lead to pathway hyperactivity in cancers. We therefore studied whether CD133 expression directly correlated with pathway activity. We made use of an activated K-Ras gene expression signature [39] to perform k-means clustering in our patient set. The group with the activated K-Ras signature was identified by gene set 
enrichment analysis (GSEA) (Suppl. Fig.4A ). The activated K-Ras cluster contained 26 patients with mutations in K-Ras or B-Raf, whereas only 9 patients with K-Ras/B-Raf mutations were found in the control group, confirming that this signature identifies activated Ras-Raf-MEK-ERK signaling, but also suggesting that not all K-Ras/B-Raf mutant CRCs display a hyperactive pathway. Tumors in the activated K-Ras cluster had a higher CD133 expression compared to the control cluster (Fig.4A) . Additionally, the activated K-Ras signature was able to predict the relapse-free survival in our patient series (p=0.0016, Fig.4B ).
So, in CRC, we can define a relation between the hyperactivation of the Ras-Raf-MEK-ERK pathway, CD133 and prognosis.
When the expression of other CSC markers were analyzed between these two clusters, some markers, like CD29 and CD44 were indeed upregulated in the activated K-Ras cluster, whereas others, like CD24 and Lgr5, were downregulated (Fig.4C) , indicating that activation of the Ras-Raf-MEK-ERK pathway does not simply increase the numbers of CSCs in these tumors, but apparently regulates, directly or indirectly, the expression of these proteins.
As CD133 has been shown to be prognostic in multiple different malignancies we wondered whether the association with Ras pathway activation would be observed in other malignancies as well. Therefore, to extend our findings to different malignancies, we made use of several publically available datasets from neuroblastoma, glioma, breast carcinoma and ovarian cancer patients [40] [41] [42] [43] . These sets represent sets of tumours with a variation in genetic background and histopathology. For instance, the glioma set contains astrocytomas, oligodendrogliomas and glioblastomas, while the breast cancer set contains both basal and luminal subtypes. However, such datasets have previously been used to determine whether CD133 is a prognostic marker mostly without regarding a potential association with a specific genetic background or histopathological subtype. K-means clustering using the K-Ras signature was performed with these datasets. Intriguingly, in all four datasets, the activated K-Ras cluster had higher average expression of CD133 compared to the normal K-Ras cluster, 1.5-fold, 2-fold, 8-fold and 3-fold respectively for neuroblastoma, glioma, breast and ovarian carcinoma (Fig.4D, Suppl.Fig.4B-E) , indicating that CD133 is also associated with an active Ras-Raf-MEK-ERK pathway in other tumor types. This does not necessarily mean Ras or Raf are mutated in these tumours, but that the pathway is hyperactive. It does however indicate that stratification based on CD133 expression does not stratify patients based on CSC, but rather serves as a pathway read-out and could potentially point to different subsets. In agreement, CD133 is clearly differentially expressed between glioblastomas, astrocytomas and oligodendrogliomas (Suppl. Fig.4F ), 
DISCUSSION
Using microarray and qPCR, we here confirm that CD133 mRNA expression can predict the relapse-free survival in stage II CRC patients. These observations are in accordance with previous data [2-7, 13, 15] . However, we show that the prognostic value of CD133 is independent of its use as a CSC marker. First of all, we previously reported that CD133 mRNA expression is not different in CSCs as compared to more differentiated tumor cells and as such CD133 mRNA cannot be used to identify CSCs. Secondly, CD133 expression did not correlate with the expression of any of the other frequently used colon CSC markers. Thirdly, neither of the other CSC markers showed any prognostic value in our cohort. Mutation analysis indicated that high CD133 expression was related to mutations in K-Ras or B-Raf.
Interestingly, it was previously shown that activation of the Ras-Raf-MEK-ERK pathway can induce the activation of CD133 promoter 5 via its nuclear target Ets, thereby inducing CD133 expression [48] . We confirmed this Ras-dependency of CD133 mRNA and protein expression The prognostic value of CD133 is thus not related to its function as CSC marker.
Interestingly, CSC isolations using CD133 are performed by FACS analysis, whereas the prognostic value is determined using either mRNA expression or IHC staining. We have shown previously that differentiation of colon CSCs does not reduce total CD133 protein or mRNA expression, while detection by the AC133 antibody by FACS is decreased.
Additionally, different IHC protocols resulted in completely different CD133 stainings. We hypothesized that this is due to differential folding of CD133 on the surface of CSCs, which may be influenced by glycosylation that affects accessibility of the AC133 epitope [27] . A recent report confirmed that N-glycosylation of CD133 determines the recognition of the AC133 epitope [28] . We therefore conclude that the level of CD133 mRNA or protein is not a reliable marker for the presence and enumeration of CSC.
Recently, we have used high Wnt activity to define the CRC CSC population [53] and used this to determine a CSC gene expression profile [38] . When this profile was used to
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on November 1, 2017. © 2012 American Association for Cancer clincancerres.aacrjournals.org Downloaded from predict prognosis in the AMC-AJCC-90 cohort, we observed that all typical Wnt target genes, including the CSC markers Lgr5 and ASCL2 were rather inversely correlated with prognosis.
Although this was due to promoter methylation of these Wnt target genes, it also points out that simple CSC marker analysis does not reflect the actual CSC numbers. Indeed, a direct comparison of CSC numbers and LGR5 and ASCL2 expression showed no correlation at all.
Moreover, the data indicated that even when analyzing complete CSC gene expression signatures the observed association does not correlate to the amount of CSCs in a tumor, but rather reflects a more immature status of the tumor [38] .
Our data do not exclude the use of CSC markers to identify and select CSCs. As mentioned above, CSC isolation is performed by selection for marker expression using either expression in the total tumor by qPCR or microarray to enumerate CSCs might therefore be problematic. We therefore conclude that the association between CD133 expression levels and patient prognosis is not reflecting the presence of CSCs, but rather points to differential Ras-Raf pathway activity.
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